Oppenheimer analyst Jay Olson maintained a Buy rating on Sierra Oncology (SRRA) yesterday and set a price target of $29.00. The company’s shares closed last Tuesday at $18.53.
According to TipRanks.com, Olson is a 3-star analyst with an average return of 2.6% and a 46.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Sierra Oncology is a Moderate Buy with an average price target of $29.00, a 55.7% upside from current levels. In a report issued on May 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $29.00 price target.
See today’s analyst top recommended stocks >>
Based on Sierra Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.92 million. In comparison, last year the company had a GAAP net loss of $31.91 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of patients with cancer. It engages in the business of researching, developing, and commercializing therapies for the treatment of patients with cancer. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.
